12:00 AM
 | 
Aug 24, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

iSonep sphingomab: Phase I data

Preliminary data from a single-arm, open-label, dose-escalation, U.S. Phase I trial in 15 patients who had not responded to at least 2 doses of Lucentis ranibizumab and/or Avastin bevacizumab showed that a single intravitreal...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >